However, in a Hungarian case–control study, use of dihydrofolate reductase inhibitors (folic acid antagonists) in pregnancy was associated with a (nonsignificant) 20% excess risk of hypospadias (Czeizel et al. 2001). This evidence concerns the gene DHFR and hypospadias.